Circulating levels of Amyloid Beta 1-40 are associated with the rate of progression of atherosclerosis in menopause

Abstract

Background: Cardiovascular disease remains a leading problem in the postmenopausal population, with a substantial proportion of unrecognized risk. Novel cardiovascular risk markers would be proven to be of benefit in developing primary prevention practices at midlife. Recent evidence is indicating that the proatherogenic aging peptide amyloid β 1-40 (Αβ1-40), may be considered as a novel biomarker in cardiovascular disease (CVD). We aimed to evaluate the possible role of plasma Αβ1-40 in the progression of atherosclerosis in postmenopausal women.